Trial Details
COMPLETEDBasic Information
| Clinical ID | c1151 |
|---|---|
| Identifier | NCT03518086 |
| Trial Title | An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Ulcerative Colitis |
| Interventions | DRUG: Mirikizumab|DRUG: Placebo |
Participant Information
| Sponsor | Eli Lilly and Company |
|---|---|
| City | Dothan |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2018-06-18 |
|---|---|
| Primary Completion Date | 2021-01-21 |
| Completion Date | 2024-05-15 |